Latest Releases
U.S. Senator Tina Smith’s Bills to Reduce the Cost of Prescription Drugs and Expand Access to Health Care Signed Into Law
WASHINGTON, D.C. [1/13/23] — More than half a dozen health care bills by U.S. Senator Tina Smith (D-Minn.) were signed into law by President Biden two weeks ago. The measures will take important steps to lower the cost of prescription drugs, address public health workforce shortages, and shore up supply chains while creating good-paying American jobs. Most of the provisions were bipartisan. “Since my first day in office, I’ve promised Minnesotans that I would work to reduce the cost of prescription drugs and expand access to health care,” said Sen. Smith. “These measures provide the tools to make significant progress on lowering health care costs, boosting our public health workforce, and more.” These new laws will: Require the Department of Health and Human Services (HHS) to establish a program to improve health outcomes and reduce health inequities. Help speed up the development of and improve access to lower-cost generic drugs by requiring the Food and Drug Administration (FDA) to make timely therapeutic equivalence evaluations for drugs approved through the complex generic pathway. This provision is based on Smith’s Modernizing Therapeutic Equivalence Rating Determination Act. Clarify the FDA’s ability to regulate combination products—products that meet both the definition of drugs and devices—as drugs rather than as devices. The provision is based on Smith’s Consistent Legal Evaluation and Regulation of Medical Products (CLEAR) Act and will eliminate unnecessary confusion and turmoil in the industry. This clarification will allow the FDA to spend more time and resources on bringing low-cost products to market to
U.S. Senator Tina Smith’s Bipartisan Mental Health Care Measures Signed Into Law
WASHINGTON, D.C. [1/13/23] — U.S. Senator Tina Smith (D-Minn.) announced two of her bipartisan mental health care bills were signed into law by President Biden two weeks ago. The provisions will take important steps to address the mental health crisis and improve Tribal health services. “I know firsthand the importance of mental health services. These measures will help expand access to mental health care in Minnesota and across this country,” said Sen. Smith. “It gives us the tools to make significant progress tackling the mental health crisis, upholding our commitments to Tribal Nations, and more.” Provisions based on Smith’s Improving Access to Behavioral Health Integration Act will provide funding for primary care practices to implement evidence-based behavioral health integration programs. In addition, the law will establish grants for Tribal governments, Tribal organizations, urban Indian organizations, and Tribal health programs to receive funds for culturally-competent mental and behavioral health services for Native Americans. The bills were included in the year-end government funding package that was recently signed into law. In addition to Smith’s mental health bills, the law also includes many other important provisions supported by Sen. Smith such as the Electoral Count Reform Act, support for the people of Ukraine, fully funding provisions of the PACT Act, permanently extending postpartum coverage for mothers on Medicaid and CHIP, increasing child care and housing access, and more.
Sens. Smith, Warren Raise Questions about Accuracy of Secretary Azar’s Testimony Blaming Pharmacy Benefit Managers for High Drug Prices
WASHINGTON, DC [08/17/18]—Today, U.S. Sens. Tina Smith (D-Minn.) and Elizabeth Warren (D-Mass.) questioned Health and Human Services (HHS) Secretary Alex Azar about his potentially misleading statements during his Senate testimony in which he blamed pharmacy benefit managers (PBMs) and drug distributors for drug manufacturers’ ongoing refusal to meaningfully reduce drug prices. The senators’ letter follows new information obtained from PBMs and drug distributors that directly contradicts the allegations made by Secretary Azar and raises questions about the accuracy of his testimony to Congress. Despite President Trump’s promises that drug companies would voluntarily enact “massive” price cuts, there have been no significant drug price
U.S. Sens. Tina Smith, Amy Klobuchar Honor the Storied Life of Minnesota’s First Female Member of Congress, Coya Knutson, with Senate Resolution
MINNESOTA [08/22/18]— Today, Minnesota’s U.S. Sens. Tina Smith and Amy Klobuchar honored the storied life of Minnesota’s first female member Congress, Coya Knutson, with a Senate Resolution heralding her life as a trailblazer who, despite great obstacles when she served in the 1950s, succeeded in making a difference for the families and communities in her state. You can read a copy of the Resolution here. The resolution, offered Wednesday on what would have been Knutson’s 106th birthday, notes that after arriving in Washington, D.C in 1954, she convinced Speaker Sam Rayburn to appoint her to be the first woman ever to serve on the House
Klobuchar, Smith, Reed Call on Administration to Protect U.S. Troops and Families from Financial Fraud
WASHINGTON – U.S. Senators Amy Klobuchar and Tina Smith joined Senator Jack Reed (D-RI) and 46 other senators in calling on the Consumer Financial Protection Bureau (CFPB) to maintain financial protections for servicemembers and their families under the Military Lending Act (MLA). Recent reports have indicated that the Administration is planning to stop examining lenders for violations of the MLA. In their letter, the senators urged CFPB Acting Director Mick Mulvaney not to end its examinations of payday lenders and other financial institutions for MLA compliance, and to not undertake measures that risk leaving U.S. troops and their families vulnerable to exploitation.
U.S. Sen. Tina Smith Presses Swiss Pharmaceutical Giant Novartis to Ensure Improper Company Actions Aren’t Pushing Up U.S. Prescription Drug Prices
WASHINGTON D.C. [08/23/18]— Today, U.S. Sen. Tina Smith (D-Minn.) pushed for answers from Swiss pharmaceutical giant Novartis on improper financial and lobbying efforts – including a $1.2 million dollar payment to President Trump’s former lawyer Michael Cohen – that could be contributing to high prescription drug prices for people in Minnesota and across the country. In May, Novartis confirmed that it erred when it paid Cohen through a shell company to help influence Trump Administration health care policy. Those payments came after Novartis had already agreed in 2016 to comply with a U.S. Securities and Exchange Commission (SEC) order to establish
English